Chief Medical Officer

A typical mandate

The company builds antibody-drug conjugates against solid tumor targets with few treatment options. Its lead program has completed dose optimization and the team is preparing for an end-of-phase 2 meeting with FDA. The board wants a medical leader who can carry the program from that meeting through a pivotal readout.

What the role owns

• Set clinical development strategy for the lead ADC and a second program approaching IND
• Lead the end-of-phase 2 interaction with FDA and shape the registrational study design
• Build and lead the clinical development, clinical science and drug safety teams
• Serve as the company's medical voice with the board, investors and key investigators
• Partner with CMC and regulatory on dose, formulation and companion diagnostic decisions
• Hold final medical accountability for patient safety across all studies

What great candidates bring

• MD or MD/PhD, with board certification or fellowship training in medical oncology preferred
• 12+ years in oncology drug development, including leadership of late-stage studies
• Direct experience leading end-of-phase 2 or pre-BLA meetings with FDA
• Working knowledge of ADC toxicity management and dose optimization under Project Optimus
• Prior experience presenting to a board and supporting financing discussions
• Credibility with academic oncology investigators and cooperative groups

Why it matters

• A seat on the executive team reporting to the CEO, with regular board access
• Meaningful equity at a stage where clinical decisions shape company value
• Full ownership of medical strategy for a program heading into a pivotal study
• Hybrid schedule, with on-site time for key cross-functional work